Stifel Financial Corp lifted its position in shares of Astrazeneca PLC (NYSE:AZN) by 4.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 376,458 shares of the company’s stock after buying an additional 16,011 shares during the period. Stifel Financial Corp’s holdings in Astrazeneca PLC were worth $12,840,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently made changes to their positions in AZN. Bank of America Corp DE raised its position in shares of Astrazeneca PLC by 29.5% during the 1st quarter. Bank of America Corp DE now owns 45,744,976 shares of the company’s stock valued at $1,424,498,000 after buying an additional 10,414,969 shares during the period. Fisher Asset Management LLC lifted its holdings in Astrazeneca PLC by 476.9% in the second quarter. Fisher Asset Management LLC now owns 11,081,856 shares of the company’s stock valued at $377,780,000 after acquiring an additional 9,160,764 shares during the last quarter. Primecap Management Co. CA lifted its holdings in Astrazeneca PLC by 32.1% in the first quarter. Primecap Management Co. CA now owns 34,310,950 shares of the company’s stock valued at $1,068,443,000 after acquiring an additional 8,330,675 shares during the last quarter. BlackRock Inc. lifted its holdings in Astrazeneca PLC by 287,844.0% in the first quarter. BlackRock Inc. now owns 6,910,657 shares of the company’s stock valued at $215,198,000 after acquiring an additional 6,908,257 shares during the last quarter. Finally, Voya Investment Management LLC lifted its holdings in Astrazeneca PLC by 38.2% in the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after acquiring an additional 662,481 shares during the last quarter. Institutional investors and hedge funds own 14.17% of the company’s stock.

Several research analysts recently weighed in on AZN shares. Sanford C. Bernstein reiterated a “buy” rating on shares of Astrazeneca PLC in a research report on Friday, September 22nd. Investec upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research report on Wednesday, August 9th. Leerink Swann downgraded Astrazeneca PLC from an “outperform” rating to a “market perform” rating and reduced their target price for the company from $36.00 to $31.00 in a research report on Thursday, July 27th. Barclays PLC reaffirmed an “overweight” rating on shares of Astrazeneca PLC in a research note on Monday, July 3rd. Finally, Argus reaffirmed a “buy” rating and issued a $35.00 price target on shares of Astrazeneca PLC in a research note on Friday, September 1st. Four investment analysts have rated the stock with a sell rating, eleven have given a hold rating and fourteen have given a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $34.20.

ILLEGAL ACTIVITY WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.watchlistnews.com/astrazeneca-plc-azn-stake-increased-by-stifel-financial-corp/1603152.html.

Shares of Astrazeneca PLC (NYSE:AZN) opened at 33.88 on Monday. The stock has a market capitalization of $85.78 billion, a price-to-earnings ratio of 22.22 and a beta of 0.76. Astrazeneca PLC has a 1-year low of $25.55 and a 1-year high of $35.60. The company’s 50 day moving average is $30.33 and its 200-day moving average is $31.81.

Astrazeneca PLC (NYSE:AZN) last announced its quarterly earnings results on Thursday, July 27th. The company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.46. Astrazeneca PLC had a return on equity of 35.90% and a net margin of 17.80%. The firm had revenue of $5.05 billion during the quarter, compared to the consensus estimate of $5.04 billion. During the same period in the prior year, the firm earned $0.83 EPS. The firm’s quarterly revenue was down 9.9% compared to the same quarter last year. Equities analysts anticipate that Astrazeneca PLC will post $1.91 earnings per share for the current fiscal year.

The business also recently disclosed a None dividend, which was paid on Monday, September 11th. Shareholders of record on Friday, August 11th were paid a dividend of $0.44 per share. This represents a dividend yield of 2.98%. The ex-dividend date of this dividend was Wednesday, August 9th. Astrazeneca PLC’s dividend payout ratio is presently 44.92%.

Astrazeneca PLC Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).

Institutional Ownership by Quarter for Astrazeneca PLC (NYSE:AZN)

Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.